Bayer: collaboration agreement with Loxo Oncology.
(CercleFinance.com) - Germany's Bayer has entered into an exclusive agreement with US-based biopharmaceutical company Loxo Oncology for the development of two novel oncology therapies.
Under the terms of the deal, both companies will jointly promote larotrectinib and LOXO-195 in the US, while Bayer will be solely responsible for the marketing of both products outside the US.
Loxo Oncology will receive an upfront payment of 400 million dollars and is eligible for 450 million dollars in milestone payments upon larotrectinib obtaining regulatory approvals and its first commercial sale, plus an additional 200 million dollars on LOXO-195.
As far as larotrectinib is concerned, the first filing is planned in the US in late 2017 or early 2018, with filing expected in the EU in 2018.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Under the terms of the deal, both companies will jointly promote larotrectinib and LOXO-195 in the US, while Bayer will be solely responsible for the marketing of both products outside the US.
Loxo Oncology will receive an upfront payment of 400 million dollars and is eligible for 450 million dollars in milestone payments upon larotrectinib obtaining regulatory approvals and its first commercial sale, plus an additional 200 million dollars on LOXO-195.
As far as larotrectinib is concerned, the first filing is planned in the US in late 2017 or early 2018, with filing expected in the EU in 2018.
Copyright (c) 2017 CercleFinance.com. All rights reserved.